• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?

作者信息

Wongariyapak Amarin, Roulstone Victoria, Melcher Alan A, Pedersen Malin, Harrington Kevin J

机构信息

Targeted Therapy Team, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.

Translational Immunotherapy Team, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.

出版信息

Ann Transl Med. 2023 Aug 30;11(10):369. doi: 10.21037/atm-2023-5. Epub 2023 Mar 17.

DOI:10.21037/atm-2023-5
PMID:37675296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10477632/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b73a/10477632/162dd01c15ad/atm-11-10-369-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b73a/10477632/162dd01c15ad/atm-11-10-369-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b73a/10477632/162dd01c15ad/atm-11-10-369-f1.jpg

相似文献

1
Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?用于晚期黑色素瘤的溶瘤病毒与免疫检查点抑制剂联合策略：有哪些证据？
Ann Transl Med. 2023 Aug 30;11(10):369. doi: 10.21037/atm-2023-5. Epub 2023 Mar 17.
2
Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.替利莫基因拉帕雷普韦克用于尿道原发性黏膜黑色素瘤在免疫检查点抑制治疗原发耐药后的应用：一例报告
Front Oncol. 2020 May 8;10:611. doi: 10.3389/fonc.2020.00611. eCollection 2020.
3
The Role of Oncolytic Viruses in the Treatment of Melanoma.溶瘤病毒在黑色素瘤治疗中的作用。
Curr Oncol Rep. 2018 Aug 25;20(10):80. doi: 10.1007/s11912-018-0729-3.
4
The safety of talimogene laherparepvec for the treatment of advanced melanoma.talimogene laherparepvec治疗晚期黑色素瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.
5
Intratumoral Immunotherapy-Update 2019.肿瘤内免疫治疗-2019 更新。
Oncologist. 2020 Mar;25(3):e423-e438. doi: 10.1634/theoncologist.2019-0438. Epub 2019 Nov 29.
6
Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.塔利莫基因拉哈帕里韦克：一种用于黑色素瘤的溶瘤病毒疗法。
Ann Pharmacother. 2017 Aug;51(8):675-681. doi: 10.1177/1060028017702654. Epub 2017 Mar 28.
7
Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?在黑色素瘤和非黑色素瘤皮肤恶性肿瘤中，溶瘤病毒目前处于什么阶段？
Pharmaceuticals (Basel). 2024 Jul 9;17(7):916. doi: 10.3390/ph17070916.
8
Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.塔利莫吉拉帕里韦综述：晚期黑色素瘤的首个溶瘤病毒类肿瘤治疗药物
J Am Acad Dermatol. 2020 Jul;83(1):189-196. doi: 10.1016/j.jaad.2020.01.039. Epub 2020 Jan 28.
9
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.瘤内注射重组人5型腺病毒（T-VEC）用于治疗晚期黑色素瘤。
Immunotherapy. 2015;7(6):611-9. doi: 10.2217/imt.15.35. Epub 2015 Jun 22.
10
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.在黑色素瘤和其他实体瘤中，将talimogene laherparepvec与免疫疗法联合使用。
Cancer Immunol Immunother. 2017 Jun;66(6):683-695. doi: 10.1007/s00262-017-1967-1. Epub 2017 Feb 25.

引用本文的文献

1
Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.放射治疗与免疫治疗联合应用的最新进展：第八届年度免疫放射会议论文集
Oncoimmunology. 2025 Dec;14(1):2507856. doi: 10.1080/2162402X.2025.2507856. Epub 2025 May 22.
2
Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?研究溶瘤病毒在黑色素瘤治疗中的潜力：我们从这里走向何方？
Skin Health Dis. 2025 Apr 22;5(2):102-113. doi: 10.1093/skinhd/vzaf022. eCollection 2025 Apr.
3
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

本文引用的文献

1
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.随机、双盲、安慰剂对照、全球 III 期试验：替莫唑胺联合替莫唑胺治疗晚期黑色素瘤。
J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23.
2
Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis.替莫唑胺胶囊单药治疗 IIIB-IVM1c 期黑色素瘤患者：系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2022 Jul;175:103705. doi: 10.1016/j.critrevonc.2022.103705. Epub 2022 May 13.
3
Oncolytic virotherapy as immunotherapy.
肿瘤浸润淋巴细胞与溶瘤腺病毒TILT-123联合治疗转移性黑色素瘤的安全性和有效性
Cell Rep Med. 2025 Mar 18;6(3):102016. doi: 10.1016/j.xcrm.2025.102016.
4
Decrease in Heparan Sulphate Binding in Tropism-Retargeted Oncolytic Herpes Simplex Virus (ReHV) Delays Blood Clearance and Improves Systemic Anticancer Efficacy.嗜性重定向溶瘤单纯疱疹病毒（ReHV）中硫酸乙酰肝素结合的减少延迟了血液清除并提高了全身抗癌疗效。
Cancers (Basel). 2024 Mar 13;16(6):1143. doi: 10.3390/cancers16061143.
溶瘤病毒治疗作为免疫疗法。
Science. 2021 Dec 10;374(6573):1325-1326. doi: 10.1126/science.abk3436. Epub 2021 Dec 9.
4
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.纳武利尤单抗联合伊匹单抗或纳武利尤单抗对比伊匹单抗治疗晚期黑色素瘤患者的长期结局。
J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.
5
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.病毒-抗体疗法：用于遗传递送达种抗体类生物疗法的基因工程溶瘤病毒。
MAbs. 2021 Jan-Dec;13(1):1982447. doi: 10.1080/19420862.2021.1982447.
6
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.T-VEC 治疗 IIIB-IVM1a 期黑色素瘤可实现高完全缓解率和持久缓解率，并与肿瘤负荷相关：一项临床预测模型研究。
Cancer Immunol Immunother. 2021 Aug;70(8):2291-2300. doi: 10.1007/s00262-020-02839-7. Epub 2021 Jan 28.
7
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.溶瘤病毒治疗介导的抗肿瘤反应：单细胞视角。
Cancer Cell. 2021 Mar 8;39(3):394-406.e4. doi: 10.1016/j.ccell.2020.12.022. Epub 2021 Jan 21.
8
Clinical landscape of oncolytic virus research in 2020.2020 年溶瘤病毒研究的临床格局。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001486.
9
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review.晚期或转移性黏膜黑色素瘤中的免疫检查点抑制剂：一项系统综述
Ther Adv Med Oncol. 2020 May 18;12:1758835920922028. doi: 10.1177/1758835920922028. eCollection 2020.
10
Treatment of Advanced Melanoma in 2020 and Beyond.2020 年及以后的晚期黑色素瘤治疗。
J Invest Dermatol. 2021 Jan;141(1):23-31. doi: 10.1016/j.jid.2020.03.943. Epub 2020 Apr 5.